We are live on
!
Find out more
DP
Diadema Partners Portfolio holdings
AUM
$588M
1-Year Est. Return
182.75%
This Fund
S&P 500
This Quarter
Est. Return
+9.46%
1 Year Est. Return
+182.75%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$233M
AUM Growth
–
Cap. Flow
+$273M
Cap. Flow
% of AUM
117.2%
Top 10 Holdings %
Top 10 Hldgs %
44.5%
Holding
107
New
107
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$9.19M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$8.94M |
| 3 |
ONC
BeOne Medicines Ltd
ONC
|
+$6.13M |
| 4 |
BPMC
Blueprint Medicines
BPMC
|
+$5.88M |
| 5 |
Teva Pharmaceuticals
TEVA
|
+$5.46M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 38.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
CALL
Relay Therapeutics
RLAY
$4.1B
| $412K | 0.18% |
+100,000
| New | +$544K |
|
77
Erasca
ERAS
$6.3B
| $394K | 0.17% |
+156,973
| New | +$430K |
|
78
CALL
Summit Therapeutics
SMMT
$10.4B
| $357K | 0.15% |
+20,000
| New | +$388K |
|
79
Zevra Therapeutics
ZVRA
$562M
| $351K | 0.15% |
+42,081
| New | +$359K |
|
80
ALX Oncology
ALXO
$261M
| $330K | 0.14% |
+197,680
| New | +$304K |
|
81
Eledon Pharmaceuticals
ELDN
$261M
| $312K | 0.13% |
+75,794
| New | +$299K |
|
|
WAVE
82
CALL
Eco Wave Power Global
WAVE
$45.5M
| $292K | 0.13% |
+23,600
| New | +$227K |
|
83
CALL
C4 Therapeutics
CCCC
$385M
| $288K | 0.12% |
+80,100
| New | +$398K |
|
84
PUT
Candel Therapeutics
CADL
$733M
| $286K | 0.12% |
+32,900
| New | +$194K |
|
|
TERN
85
DELISTED
Terns Pharmaceuticals
TERN
| $279K | 0.12% |
+50,370
| New | +$341K |
|
86
PUT
Biomea Fusion
BMEA
$84.6M
| $277K | 0.12% |
+71,400
| New | +$569K |
|
87
CALL
Gossamer Bio
GOSS
$82.9M
| $232K | 0.1% |
+256,900
| New | +$220K |
|
|
88
Gossamer Bio
GOSS
$82.9M
| $197K | 0.08% |
+217,987
| New | +$187K |
|
|
89
Candel Therapeutics
CADL
$733M
| $174K | 0.07% |
+20,000
| New | +$118K |
|
|
90
PUT
Summit Therapeutics
SMMT
$10.4B
| $152K | 0.07% |
+8,500
| New | +$165K |
|
91
PUT
Q32 Bio
QTTB
$466M
| $121K | 0.05% |
+35,100
| New | +$1.11M |
|
92
SAB Biotherapeutics
SABS
$273M
| $114K | 0.05% |
+30,000
| New | +$98.5K |
|
|
CMRX
93
DELISTED
Chimerix, Inc.
CMRX
| $101K | 0.04% |
+29,082
| New | +$41K |
|
94
CALL
Kodiak Sciences
KOD
$2.6B
| $72.6K | 0.03% |
+7,300
| New | +$42K |
|
|
95
Q32 Bio
QTTB
$466M
| $67.8K | 0.03% |
+19,700
| New | +$622K |
|
96
PUT
Larimar Therapeutics
LRMR
$397M
| $65.4K | 0.03% |
+16,900
| New | +$112K |
|
|
97
CALL
ALX Oncology
ALXO
$261M
| $65K | 0.03% |
+38,900
| New | +$59.8K |
|
98
PUT
Arvinas
ARVN
$518M
| $44.1K | 0.02% |
+2,300
| New | +$55.9K |
|
99
Edgewise Therapeutics
EWTX
$4.13B
| $36.3K | 0.02% |
+1,359
| New | +$43.3K |
|
100
CALL
ARS Pharmaceuticals
SPRY
$509M
| $33.8K | 0.01% |
+3,200
| New | +$44.8K |
|
Similar funds
MC
PFG
FMI
EGWAG
PFG
GIM
FL
BA
Diadema Partners's Q4 2024 Portfolio in Review
Q4 2024 is the first quarter with a 13F filing on record for Diadema Partners, which disclosed 107 positions worth $233M. Its ten largest holdings account for 44% of the portfolio.
Its largest position is AbbVie: 50,000 shares worth $8.88M.
By sector, the portfolio is most concentrated in Healthcare at 38% of assets.
- Diadema Partners's largest Q4 2024 buy was AbbVie: 50,000 shares worth $8.88M.
- Diadema Partners's ten largest holdings make up 44% of its $233M portfolio in Q4 2024.
- Diadema Partners disclosed 107 positions in Q4 2024, its first 13F filing on record.
Based on Diadema Partners's 13F filing for Q4 2024, filed 14 Feb 2025.